Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Amrutanjan Health Care's 9-Day RSI or its related term are showing as below:
NSE:AMRUTANJAN's 9-Day RSI is ranked better than 68.1% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 41.65
vs NSE:AMRUTANJAN: 35.17
Amrutanjan Health Care (NSE:AMRUTANJAN) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Amrutanjan Health Care 9-Day RSI Related Terms
NSE:AMRUTANJAN vs ZTS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amrutanjan Health Care's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amrutanjan Health Care 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amrutanjan Health Care's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Amrutanjan Health Care's 9-Day RSI falls into.
Amrutanjan Health Care (NSE:AMRUTANJAN) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amrutanjan Health Care (NSE:AMRUTANJAN) has a 9-Day RSI of 35.17 as of Sep. 14, 2026. According to the industry distribution chart, Amrutanjan Health Care ranks #334 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is Amrutanjan Health Care's 9-Day RSI too high?
Amrutanjan Health Care's current 9-Day RSI is 35.17. The Drug Manufacturers industry median 9-Day RSI is 41.65. Amrutanjan Health Care's value of 35.17 is 15.6% below this industry median. Based on the distribution chart, Amrutanjan Health Care ranks #334 out of 1047 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amrutanjan Health Care has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amrutanjan Health Care's 9-Day RSI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amrutanjan Health Care ranks #334 out of 1047 companies for 9-Day RSI. This puts Amrutanjan Health Care in the upper half of its industry. The industry median 9-Day RSI is 41.65. Amrutanjan Health Care's value of 35.17 is 15.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 41.65, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amrutanjan Health Care's current 9-Day RSI of 35.17 is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 41.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amrutanjan Health Care's current 9-Day RSI is 35.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amrutanjan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Amrutanjan Health Care (NSE:AMRUTANJAN) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹830.57, compared to a current price of ₹490.95 — trading 40.9% below its estimated fair value. The current 9-Day RSI is 35.17 and 15.6% below the Drug Manufacturers industry median of 41.65. Amrutanjan Health Care's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Amrutanjan Health Care (NSE:AMRUTANJAN), the current 9-Day RSI is 35.17 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amrutanjan Health Care (NSE:AMRUTANJAN) Overvalued in 2026?
Based on GuruFocus' analysis, Amrutanjan Health Care stock appears to be undervalued.
The current stock price of ₹490.95 is trading 40.9% below its estimated GF Value™ of ₹830.57.
GuruFocus considers Amrutanjan Health Care to be Significantly Undervalued.
Key valuation signals for NSE:AMRUTANJAN:
9-Day RSI: 35.17
GF Value™: ₹830.57 vs. price of ₹490.95 (40.9% below fair value)
Industry Position: 15.6% below the Drug Manufacturers median (#334 of 1047)
No single metric tells the full story. See the NSE:AMRUTANJAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amrutanjan Health Care Ltd manufactures Ayurvedic and allopathic products. The company operates through the following segments: OTC Products, Beverages, and Others. The majority of the revenue is generated from its OTC segment which is engaged in the manufacturing products of pain management, congestion management, and hygiene. Its beverage segment includes manufacturing fruit juices and oral rehydration drinks. Some of its products include Roll-on, Spray, Balm, Cough Syrup, Sanitary napkins, and inhalers. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for NSE:AMRUTANJAN
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AMRUTANJAN has been successfully added to your 
